Literature DB >> 20172695

Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients.

Margaret K Vernon1, Dennis A Revicki, A George Awad, Riad Dirani, Jessica Panish, Carla M Canuso, Augusto Grinspan, Sally Mannix, Amir H Kalali.   

Abstract

The Medication Satisfaction Questionnaire (MSQ) is a single-item questionnaire which evaluates satisfaction with antipsychotic medication in schizophrenia patients. This study evaluated the reliability and validity for its use in research and clinical settings. Data pooled across treatment groups (control vs. Paliperidone ER) from a randomized 6-week study were used to conduct four psychometric assessments of the MSQ: (1) test-retest reliability, (2) convergent validity, (3) known-groups validity, and (4) minimally important difference (MID). This analysis included 191 randomized subjects. Test-retest reliability was evaluated for patients with no change in satisfaction from weeks 2 to 4 and weeks 4 to 6 (ICC=0.80; 0.83, respectively). Convergent validity was demonstrated through large correlations with Treatment Satisfaction Questionnaire for Medication (TSQM) global score (r=0.72-0.77), and through small correlations with variables measuring clinical symptoms and functioning (e.g., Positive and Negative Syndrome Scale (PANSS) total score [r=-0.30 to -0.17], CGI-S [r=-0.35 to -0.27], SF-36 Physical Functioning Score [r=0.18] and side effects and extrapiramidal measures (including UKU, ESRS-A, SAS). Mean MSQ scores were significantly different between those who completed and discontinued the study, and between different satisfaction groups based on TSQM, demonstrating good known-groups validity. MID estimates for the MSQ ranged from 0.47 (standard error of measurement) to 0.58 (anchor-based method). Results suggest that the MSQ has acceptable reliability and validity, making this single-item questionnaire appropriate and easy to use in clinical research and potentially in clinical practice. A 1-point change on the MSQ may be considered clinically meaningful. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20172695     DOI: 10.1016/j.schres.2010.01.021

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  27 in total

1.  Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.

Authors:  Pablo Barrio; Lluisa Ortega; Josep Guardia; Carlos Roncero; Lara Yuguero; Antoni Gual
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 2.  Treatment satisfaction instruments for different purposes during a product's lifecycle: keeping the end in mind.

Authors:  Diana Rofail; Fiona Taylor; Antoine Regnault; Anna Filonenko
Journal:  Patient       Date:  2011       Impact factor: 3.883

3.  Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia.

Authors:  Stefan Leucht; Johannes Hamann; Spyridon Siafis; Nicola Bursch; Katharina Müller; Lisa Schmid; Florian Schuster; Jakob Waibel; Tri Huynh; Florian Matthes; Alessandro Rodolico; Peter Brieger; Markus Bühner; Stephan Heres
Journal:  BMC Psychiatry       Date:  2022-06-17       Impact factor: 4.144

4.  Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial.

Authors:  M Eugenia Socias; Evan Wood; Huiru Dong; Rupinder Brar; Paxton Bach; Sean M Murphy; Nadia Fairbairn
Journal:  Contemp Clin Trials       Date:  2020-03-16       Impact factor: 2.226

Review 5.  The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

6.  Usefulness of the Psoriatic Arthritis Screening and Evaluation Questionnaire to Monitor Disease Activity in Management of Patients with Psoriasis: Findings from the EPI-PSODE Study.

Authors:  Yong Beom Choe; Chul Jong Park; Dae Young Yu; Youngdoe Kim; Hyun Jeong Ju; Sang Woong Youn; Joo-Heung Lee; Byung Soo Kim; Seong Jun Seo; Seok-Kweon Yun; Joonsoo Park; Nack In Kim; Jai Il Youn; Seok-Jong Lee; Min-Geol Lee; Kwang Joong Kim; Young Suck Ro; Hae Jun Song; Bong Seok Shin; Sung Ku Ahn; Ji Yeoun Lee; Young Ho Won; Min Soo Jang; Ki Ho Kim; Myung Hwa Kim; Tae Yoon Kim; Jee-Ho Choi
Journal:  Ann Dermatol       Date:  2019-01-02       Impact factor: 1.444

7.  Minimally important difference of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q).

Authors:  Javier Rejas; Miguel A Ruiz; Antonio Pardo; Javier Soto
Journal:  BMC Med Res Methodol       Date:  2011-10-20       Impact factor: 4.615

8.  Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.

Authors:  Leslie Citrome; Peter J Weiden; Joseph P McEvoy; Christoph U Correll; Josephine Cucchiaro; Jay Hsu; Antony Loebel
Journal:  CNS Spectr       Date:  2013-12-16       Impact factor: 3.790

9.  Opti-Med: the effectiveness of optimised clinical medication reviews in older people with 'geriatric giants' in general practice; study protocol of a cluster randomised controlled trial.

Authors:  Floor Willeboordse; Jacqueline G Hugtenburg; Liset van Dijk; Judith E Bosmans; Oscar J de Vries; François G Schellevis; Petra J M Elders
Journal:  BMC Geriatr       Date:  2014-11-18       Impact factor: 3.921

10.  Towards a framework for treatment effectiveness in schizophrenia.

Authors:  Georg Juckel; Andrea de Bartolomeis; Philip Gorwood; Sergey Mosolov; Luca Pani; Alessandro Rossi; Julio Sanjuan
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-24       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.